Sanofi/Alnylam's haemophilia drug hits another safety speed-...

Sanofi’s attempt to take on Roche with a ground-breaking approach to treating haemophilia has hit a setback after the company voluntarily placed its late-stage trials of fitusiran on hold b

Novo Nordisk builds in haemophilia with Bluebird Bio gene ed...

NHS reimburses Roche's Hemlibra in new group of haemophilia ...

NHS England has agreed to reimburse Roche’s Hemlibra (emicizumab) in a new group of patients with haemophilia A, widening access to the potentially life-saving drug.

Catalyst’s rival to NovoSeven hits the mark in phase 2 haemo...

BioMarin seeks haemophilia gene therapy approval after promi...

BioMarin is set to file for approval for its haemophilia gene therapy valoctocogene roxaparvovec, after it achieved pre-specified clinical criteria for regulatory review.

The unmet needs of bleeding disorder patients

Ahead of eyeforpharma Philadelphia 2019, we talk to speaker and haemophilia advocate Michelle Rice about the changing landscape for bleeding disorders